Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Juan‐Luis Sanz
A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer
Anti-Cancer Drugs
Cancer Research
Oncology
Pharmacology
A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer
Cancer
Cancer Research
Oncology
A Randomized Phase II Study Evaluating Different Maintenance Schedules of Nab-Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer: Final Results of the IBCSG 42-12/Big 2-12 SNAP Trial
Annals of Oncology
Medicine
Oncology
Hematology
Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial
BMC Cancer
Cancer Research
Oncology
Genetics
Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials
Oncotarget
Oncology
Comparative Effectiveness of Early-Line Nab-Paclitaxel vs. Paclitaxel in Patients With Metastatic Breast Cancer: A US Community-Based Real-World Analysis
Cancer Management and Research
Oncology
Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial
Breast Care
Surgery
Oncology
Chromosome 17 Polysomy Without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared With Paclitaxel in Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Individually Tailored Treatment With Epirubicin and Paclitaxel With or Without Capecitabine as First-Line Chemotherapy in Metastatic Breast Cancer: A Randomized Multicenter Trial
Breast Cancer Research and Treatment
Cancer Research
Oncology
